Who
Kirsten Flowers
Director
Company insider
Files Form 4 as: Director, PMV Pharmaceuticals; Director, Comera Life Sciences Holdings; CCO & Chief Strategy Officer, Kura Oncology.
In numbers
- Trades disclosed
- 21
- Buys
- 1
- Sells
- 1
- Bought
- $17K
- Sold
- $26K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 6 Jan 2020
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,500 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 9 Nov 2023filed 14 Nov 2023 | Comera Life Sciences Holdingsoption or derivative | SEC FORM 4 Code A | —111,494 at $0.00 | filing |
| 31 Aug 2023filed 1 Sep 2023 | Comera Life Sciences Holdingsoption or derivative | SEC FORM 4 Code A | —67,172 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 12 May 2023filed 16 May 2023 | Comera Life Sciences Holdingsoption or derivative | SEC FORM 4 Code A | —39,491 at $0.00 | filing |
| 14 Feb 2023filed 16 Feb 2023 | Comera Life Sciences Holdingsoption or derivative | SEC FORM 4 Code A | —7,100 at $0.00 | filing |
| 27 Jan 2023filed 31 Jan 2023 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $26K1,906 at $13.89 | filing |
| 4 Jan 2023filed 14 Feb 2023 | Comera Life Sciences Holdingsoption or derivative | SEC FORM 4 Code P | $3,37813,513 at $0.25 | filing |
| 4 Jan 2023filed 14 Feb 2023 | Comera Life Sciences Holdings | SEC FORM 4 Bought | $17K13,513 at $1.23 | filing |
| 4 Jan 2023filed 6 Jan 2023 | Comera Life Sciences Holdingsoption or derivative | SEC FORM 4 Code A | $3,37813,513 at $0.25 | filing |
| 4 Jan 2023filed 6 Jan 2023 | Comera Life Sciences Holdings | SEC FORM 4 Code A | $17K13,513 at $1.23 | filing |
| 2 Jun 2022filed 6 Jun 2022 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 19 May 2022filed 14 Feb 2023 | Comera Life Sciences Holdingsoption or derivative | SEC FORM 4 Code A | —44,981 | filing |
| 26 Jan 2022filed 28 Jan 2022 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —171,000 at $0.00 | filing |
| 26 Jan 2022filed 28 Jan 2022 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —21,900 at $0.00 | filing |
| 6 Jan 2022filed 10 Jan 2022 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —32,677 at $0.00 | filing |
| 26 Jan 2021filed 28 Jan 2021 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in DiabetesKURA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Kirsten Flowers; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.